Key Takeaways
- A Johns Hopkins vaccine called mKRAS-VAX trained the immune system to spot mutated KRAS in 18 of 20 high-risk people, and the T-cell response lasted up to two years.
- Over a median 16.5 months, none of the vaccinated participants developed pancreatic cancer, and eight had pancreatic lesions shrink or resolve.
- This is a phase 1 prevention trial in healthy high-risk people, not a cancer treatment, and it was too small to prove the vaccine caused the benefit.
Trying to stop the cancer nobody catches in time
Pancreatic cancer is so lethal largely because we find it late. There is no good early screen, and by the time symptoms show, it is usually advanced. So the strategy behind this trial is different from most cancer research: not treat the tumor, but stop it from ever forming in people we already know are at high risk.
The vaccine, mKRAS-VAX, comes from the Sidney Kimmel Cancer Center at Johns Hopkins, with the trial led by Elizabeth M. Jaffee, MD. It is an off-the-shelf synthetic peptide vaccine, meaning it is not custom-built per patient, aimed at the six most common KRAS mutations that turn up in pancreatic tumors and in the precancerous lesions that precede them.
Why KRAS is the target
Think of KRAS as an accelerator pedal for cell growth. When it mutates, the pedal jams down, and cells keep dividing when they should stop. That single broken gene sits behind most pancreatic cancers, which is exactly what makes it useful here: it is a shared flaw. A vaccine that teaches immune cells to recognize mutated KRAS peptides can, in principle, work across many different patients rather than being tailored to one.
What the phase 1 data showed
The trial enrolled 20 healthy people (median age 66.5) with a genetic predisposition to pancreatic cancer and evidence of pancreatic lesions.
| Result | Finding |
|---|---|
| KRAS-specific T-cell response | 18 of 20 participants (90%) |
| Durability | Detectable in blood up to 2 years |
| Median follow-up | 16.5 months |
| Cancers during follow-up | None |
| Lesion changes (16 imaged) | 5 cyst resolutions, 3 partial regressions |
Ninety percent of participants mounted the immune response the vaccine was designed to trigger, and it held for the long haul, still measurable two years out. On imaging, some precancerous lesions actually got smaller or disappeared.
Read it with the right caution
The lesion regressions are the eye-catching part, and also the part to be most careful with. Twenty people is a tiny group, and a phase 1 trial is built to check safety and whether the vaccine provokes an immune response, not to prove it prevents cancer. Lesions can change on their own. Nobody can yet say the vaccine is why these shrank.
What the results do earn is a bigger trial. The findings were published in Cancer Discovery, and the durable, high response rate is a genuine reason to keep going. For a disease this deadly, a safe shot that reliably wakes the immune system against the mutation driving it is worth chasing hard, as long as the next study is the one that tests whether it actually stops cancers, not just whether it stirs T cells.
Sources:
- Medscape, “Vaccine to Prevent Pancreatic Cancer Shows Early Promise”
- Healio, “Vaccine designed to ‘intercept’ pancreatic cancer induces durable responses”
- GEN, “KRAS-Targeted Vaccine Crosses First Clinical Milestone in Pancreatic Cancer Prevention”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.